E-cigarette and Vape
E-cigarette and Vape market is segmented by region (country), players, by Type and by Application ... Read More
Global and United States Hemoglobinopathies Market Report & Forecast 2023-2028
1 Study Coverage
1.1 Hemoglobinopathies Revenue in Hemoglobinopathies Business (2017-2022) & (US$ Million) Introduction
1.2 Global Hemoglobinopathies Outlook 2017 VS 2022 VS 2028
1.2.1 Global Hemoglobinopathies Market Size for the Year 2017-2028
1.2.2 Global Hemoglobinopathies Market Size for the Year 2017-2028
1.3 Hemoglobinopathies Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.3.1 The Market Share of United States Hemoglobinopathies in Global, 2017 VS 2022 VS 2028
1.3.2 The Growth Rate of Hemoglobinopathies Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.4 Hemoglobinopathies Market Dynamics
1.4.1 Hemoglobinopathies Industry Trends
1.4.2 Hemoglobinopathies Market Drivers
1.4.3 Hemoglobinopathies Market Challenges
1.4.4 Hemoglobinopathies Market Restraints
1.5 Study Objectives
1.6 Years Considered
2 Hemoglobinopathies by Type
2.1 Hemoglobinopathies Market Segment by Type
2.1.1 Blood Transfusion
2.1.2 Iron Chelation Therapy
2.1.3 Bone Marrow Transplant
2.1.4 Others
2.2 Global Hemoglobinopathies Market Size by Type (2017, 2022 & 2028)
2.3 Global Hemoglobinopathies Market Size by Type (2017-2028)
2.4 United States Hemoglobinopathies Market Size by Type (2017, 2022 & 2028)
2.5 United States Hemoglobinopathies Market Size by Type (2017-2028)
3 Hemoglobinopathies by Application
3.1 Hemoglobinopathies Market Segment by Application
3.1.1 Blood Testing
3.1.2 Genetic Testing
3.1.3 Pre-Implantation Genetic Diagnosis (PGD)
3.1.4 Others
3.2 Global Hemoglobinopathies Market Size by Application (2017, 2022 & 2028)
3.3 Global Hemoglobinopathies Market Size by Application (2017-2028)
3.4 United States Hemoglobinopathies Market Size by Application (2017, 2022 & 2028)
3.5 United States Hemoglobinopathies Market Size by Application (2017-2028)
4 Global Hemoglobinopathies Competitor Landscape by Company
4.1 Global Hemoglobinopathies Market Size by Company
4.1.1 Top Global Hemoglobinopathies Companies Ranked by Revenue (2021)
4.1.2 Global Hemoglobinopathies Revenue by Player (2017-2022)
4.2 Global Hemoglobinopathies Concentration Ratio (CR)
4.2.1 Hemoglobinopathies Market Concentration Ratio (CR) (2017-2022)
4.2.2 Global Top 5 and Top 10 Largest Companies of Hemoglobinopathies in 2021
4.2.3 Global Hemoglobinopathies Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.3 Global Hemoglobinopathies Headquarters, Revenue in Hemoglobinopathies Business (2017-2022) & (US$ Million) Type
4.3.1 Global Hemoglobinopathies Headquarters and Area Served
4.3.2 Global Hemoglobinopathies Companies Revenue in Hemoglobinopathies Business (2017-2022) & (US$ Million) Type
4.3.3 Date of International Companies Enter into Hemoglobinopathies Market
4.4 Companies Mergers & Acquisitions, Expansion Plans
4.5 United States Hemoglobinopathies Market Size by Company
4.5.1 Top Hemoglobinopathies Players in United States, Ranked by Revenue (2021)
4.5.2 United States Hemoglobinopathies Revenue by Players (2020, 2021 & 2022)
5 Global Hemoglobinopathies Market Size by Region
5.1 Global Hemoglobinopathies Market Size by Region: 2017 VS 2022 VS 2028
5.2 Global Hemoglobinopathies Market Size by Region (2017-2028)
5.2.1 Global Hemoglobinopathies Market Size by Region: 2017-2022
5.2.2 Global Hemoglobinopathies Market Size by Region (2023-2028)
6 Segment in Region Level & Country Level
6.1 North America
6.1.1 North America Hemoglobinopathies Market Size YoY Growth 2017-2028
6.1.2 North America Hemoglobinopathies Market Facts & Figures by Country (2017, 2022 & 2028)
6.1.3 U.S.
6.1.4 Canada
6.2 Asia-Pacific
6.2.1 Asia-Pacific Hemoglobinopathies Market Size YoY Growth 2017-2028
6.2.2 Asia-Pacific Hemoglobinopathies Market Facts & Figures by Region (2017, 2022 & 2028)
6.2.3 China
6.2.4 Japan
6.2.5 South Korea
6.2.6 India
6.2.7 Australia
6.2.8 Taiwan
6.2.9 Indonesia
6.2.10 Thailand
6.2.11 Malaysia
6.2.12 Philippines
6.3 Europe
6.3.1 Europe Hemoglobinopathies Market Size YoY Growth 2017-2028
6.3.2 Europe Hemoglobinopathies Market Facts & Figures by Country (2017, 2022 & 2028)
6.3.3 Germany
6.3.4 France
6.3.5 U.K.
6.3.6 Italy
6.3.7 Russia
6.4 Latin America
6.4.1 Latin America Hemoglobinopathies Market Size YoY Growth 2017-2028
6.4.2 Latin America Hemoglobinopathies Market Facts & Figures by Country (2017, 2022 & 2028)
6.4.3 Mexico
6.4.4 Brazil
6.4.5 Argentina
6.5 Middle East and Africa
6.5.1 Middle East and Africa Hemoglobinopathies Market Size YoY Growth 2017-2028
6.5.2 Middle East and Africa Hemoglobinopathies Market Facts & Figures by Country (2017, 2022 & 2028)
6.5.3 Turkey
6.5.4 Saudi Arabia
6.5.5 U.A.E
7 Company Profiles
7.1 Gamida Cell
7.1.1 Gamida Cell Company Details
7.1.2 Gamida Cell Business Overview
7.1.3 Gamida Cell Hemoglobinopathies Introduction
7.1.4 Gamida Cell Revenue in Hemoglobinopathies Business (2017-2022)
7.1.5 Gamida Cell Recent Development
7.2 Alnylam Pharmaceuticals
7.2.1 Alnylam Pharmaceuticals Company Details
7.2.2 Alnylam Pharmaceuticals Business Overview
7.2.3 Alnylam Pharmaceuticals Hemoglobinopathies Introduction
7.2.4 Alnylam Pharmaceuticals Revenue in Hemoglobinopathies Business (2017-2022)
7.2.5 Alnylam Pharmaceuticals Recent Development
7.3 Sanofi
7.3.1 Sanofi Company Details
7.3.2 Sanofi Business Overview
7.3.3 Sanofi Hemoglobinopathies Introduction
7.3.4 Sanofi Revenue in Hemoglobinopathies Business (2017-2022)
7.3.5 Sanofi Recent Development
7.4 Sangamo Therapeutics Inc.
7.4.1 Sangamo Therapeutics Inc. Company Details
7.4.2 Sangamo Therapeutics Inc. Business Overview
7.4.3 Sangamo Therapeutics Inc. Hemoglobinopathies Introduction
7.4.4 Sangamo Therapeutics Inc. Revenue in Hemoglobinopathies Business (2017-2022)
7.4.5 Sangamo Therapeutics Inc. Recent Development
7.5 Global Blood Therapeutics
7.5.1 Global Blood Therapeutics Company Details
7.5.2 Global Blood Therapeutics Business Overview
7.5.3 Global Blood Therapeutics Hemoglobinopathies Introduction
7.5.4 Global Blood Therapeutics Revenue in Hemoglobinopathies Business (2017-2022)
7.5.5 Global Blood Therapeutics Recent Development
7.6 Bluebird Bio
7.6.1 Bluebird Bio Company Details
7.6.2 Bluebird Bio Business Overview
7.6.3 Bluebird Bio Hemoglobinopathies Introduction
7.6.4 Bluebird Bio Revenue in Hemoglobinopathies Business (2017-2022)
7.6.5 Bluebird Bio Recent Development
7.7 Emmaus Life Sciences Inc.
7.7.1 Emmaus Life Sciences Inc. Company Details
7.7.2 Emmaus Life Sciences Inc. Business Overview
7.7.3 Emmaus Life Sciences Inc. Hemoglobinopathies Introduction
7.7.4 Emmaus Life Sciences Inc. Revenue in Hemoglobinopathies Business (2017-2022)
7.7.5 Emmaus Life Sciences Inc. Recent Development
7.8 Prolong Pharmaceuticals
7.8.1 Prolong Pharmaceuticals Company Details
7.8.2 Prolong Pharmaceuticals Business Overview
7.8.3 Prolong Pharmaceuticals Hemoglobinopathies Introduction
7.8.4 Prolong Pharmaceuticals Revenue in Hemoglobinopathies Business (2017-2022)
7.8.5 Prolong Pharmaceuticals Recent Development
7.9 Celgene Corporation
7.9.1 Celgene Corporation Company Details
7.9.2 Celgene Corporation Business Overview
7.9.3 Celgene Corporation Hemoglobinopathies Introduction
7.9.4 Celgene Corporation Revenue in Hemoglobinopathies Business (2017-2022)
7.9.5 Celgene Corporation Recent Development
8 Research Findings and Conclusion
9 Appendix
9.1 Research Methodology
9.1.1 Methodology/Research Approach
9.1.2 Data Source
9.2 Author Details
9.3 Disclaimer
List of Tables
Table 1. Hemoglobinopathies Market Size United States VS Global, CAGR (2017 VS 2022 VS 2028)
Table 2. Hemoglobinopathies Market Trends
Table 3. Hemoglobinopathies Market Drivers
Table 4. Hemoglobinopathies Market Challenges
Table 5. Hemoglobinopathies Market Restraints
Table 6. Global Hemoglobinopathies Market Size by Type: 2017 VS 2022 VS 2028 (US$ Million)
Table 7. United States Hemoglobinopathies Market Size by Type: 2017 VS 2022 VS 2028 (US$ Million)
Table 8. Global Hemoglobinopathies Market Size by Application: 2017 VS 2022 VS 2028 (US$ Million)
Table 9. United States Hemoglobinopathies Market Size by Application: 2017 VS 2022 VS 2028 (US$ Million)
Table 10. Top Hemoglobinopathies Companies in Global Market, Ranking by Revenue (2021)
Table 11. Global Hemoglobinopathies Revenue by Player, (US$ Million), 2017-2022
Table 12. Global Hemoglobinopathies Revenue Share by Player, 2017-2022
Table 13. Global Hemoglobinopathies Companies Market Concentration Ratio (CR5 and HHI)
Table 14. Global Hemoglobinopathies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hemoglobinopathies as of 2021)
Table 15. Top Players of Hemoglobinopathies in Global Market, Headquarters and Area Served
Table 16. Companies Revenue in Hemoglobinopathies Business (2017-2022) & (US$ Million) Type
Table 17. Date of International Companies Enter into Hemoglobinopathies Market
Table 18. Companies Mergers & Acquisitions, Expansion Plans
Table 19. Top Hemoglobinopathies Players in United States Market, Ranking by Revenue (2021)
Table 20. United States Hemoglobinopathies Revenue by Players, (US$ Million), 2020, 2021 & 2022
Table 21. United States Hemoglobinopathies Revenue Share by Players, 2020, 2021 & 2022
Table 22. Global Hemoglobinopathies Market Size by Region (US$ Million): 2017 VS 2022 VS 2028
Table 23. Global Hemoglobinopathies Market Size by Region (2017-2022) & (US$ Million)
Table 24. Global Hemoglobinopathies Market Size Forecast by Region (2023-2028) & (US$ Million)
Table 25. North America Hemoglobinopathies Sales in Value by Country (2017-2028) & (US$ Million)
Table 26. Asia Pacific Hemoglobinopathies Sales in Value by Region (2017-2028) & (US$ Million)
Table 27. Europe Hemoglobinopathies Sales in Value by Country (2017-2028) & (US$ Million)
Table 28. Latin Americaa Hemoglobinopathies Sales in Value by Country (2017-2028) & (US$ Million)
Table 29. Middle East and Africa Hemoglobinopathies Sales in Value by Country (2017-2028) & (US$ Million)
Table 30. Gamida Cell Company Details
Table 31. Gamida Cell Business Overview
Table 32. Gamida Cell Hemoglobinopathies Product
Table 33. Gamida Cell Revenue in Hemoglobinopathies Business (2017-2022) & (US$ Million)
Table 34. Gamida Cell Recent Development
Table 35. Alnylam Pharmaceuticals Company Details
Table 36. Alnylam Pharmaceuticals Business Overview
Table 37. Alnylam Pharmaceuticals Hemoglobinopathies Product
Table 38. Alnylam Pharmaceuticals Revenue in Hemoglobinopathies Business (2017-2022) & (US$ Million)
Table 39. Alnylam Pharmaceuticals Recent Development
Table 40. Sanofi Company Details
Table 41. Sanofi Business Overview
Table 42. Sanofi Hemoglobinopathies Product
Table 43. Sanofi Revenue in Hemoglobinopathies Business (2017-2022) & (US$ Million)
Table 44. Sanofi Recent Development
Table 45. Sangamo Therapeutics Inc. Company Details
Table 46. Sangamo Therapeutics Inc. Business Overview
Table 47. Sangamo Therapeutics Inc. Hemoglobinopathies Product
Table 48. Sangamo Therapeutics Inc. Revenue in Hemoglobinopathies Business (2017-2022) & (US$ Million)
Table 49. Sangamo Therapeutics Inc. Recent Development
Table 50. Global Blood Therapeutics Company Details
Table 51. Global Blood Therapeutics Business Overview
Table 52. Global Blood Therapeutics Hemoglobinopathies Product
Table 53. Global Blood Therapeutics Revenue in Hemoglobinopathies Business (2017-2022) & (US$ Million)
Table 54. Global Blood Therapeutics Recent Development
Table 55. Bluebird Bio Company Details
Table 56. Bluebird Bio Business Overview
Table 57. Bluebird Bio Hemoglobinopathies Product
Table 58. Bluebird Bio Revenue in Hemoglobinopathies Business (2017-2022) & (US$ Million)
Table 59. Bluebird Bio Recent Development
Table 60. Emmaus Life Sciences Inc. Company Details
Table 61. Emmaus Life Sciences Inc. Business Overview
Table 62. Emmaus Life Sciences Inc. Hemoglobinopathies Product
Table 63. Emmaus Life Sciences Inc. Revenue in Hemoglobinopathies Business (2017-2022) & (US$ Million)
Table 64. Emmaus Life Sciences Inc. Recent Development
Table 65. Prolong Pharmaceuticals Company Details
Table 66. Prolong Pharmaceuticals Business Overview
Table 67. Prolong Pharmaceuticals Hemoglobinopathies Product
Table 68. Prolong Pharmaceuticals Revenue in Hemoglobinopathies Business (2017-2022) & (US$ Million)
Table 69. Prolong Pharmaceuticals Recent Development
Table 70. Celgene Corporation Company Details
Table 71. Celgene Corporation Business Overview
Table 72. Celgene Corporation Hemoglobinopathies Product
Table 73. Celgene Corporation Revenue in Hemoglobinopathies Business (2017-2022) & (US$ Million)
Table 74. Celgene Corporation Recent Development
Table 75. Research Programs/Design for This Report
Table 76. Key Data Information from Secondary Sources
Table 77. Key Data Information from Primary Sources
List of Figures
Figure 1. Hemoglobinopathies Product Picture
Figure 2. Global Hemoglobinopathies Market Size, (US$ Million), 2017 VS 2022 VS 2028
Figure 3. Global Hemoglobinopathies Market Size 2017-2028 (US$ Million)
Figure 4. United States Hemoglobinopathies Market Size, (US$ Million), 2017 VS 2022 VS 2028
Figure 5. United States Hemoglobinopathies Market Size 2017-2028 (US$ Million)
Figure 6. United States Hemoglobinopathies Market Share in Global 2017-2028
Figure 7. Hemoglobinopathies Report Years Considered
Figure 8. Product Picture of Blood Transfusion
Figure 9. Product Picture of Iron Chelation Therapy
Figure 10. Product Picture of Bone Marrow Transplant
Figure 11. Product Picture of Others
Figure 12. Global Hemoglobinopathies Market Share by Type in 2022 & 2028
Figure 13. Global Hemoglobinopathies Market Size by Type (2017-2028) & (US$ Million)
Figure 14. Global Hemoglobinopathies Market Share by Type (2017-2028)
Figure 15. United States Hemoglobinopathies Market Share by Type in 2022 & 2028
Figure 16. United States Hemoglobinopathies Market Size by Type (2017-2028) & (US$ Million)
Figure 17. United States Hemoglobinopathies Market Share by Type (2017-2028)
Figure 18. Product Picture of Blood Testing
Figure 19. Product Picture of Genetic Testing
Figure 20. Product Picture of Pre-Implantation Genetic Diagnosis (PGD)
Figure 21. Product Picture of Others
Figure 22. Global Hemoglobinopathies Market Share by Application in 2022 & 2028
Figure 23. Global Hemoglobinopathies Market Size by Application (2017-2028) & (US$ Million)
Figure 24. Global Hemoglobinopathies Market Share by Application (2017-2028)
Figure 25. United States Hemoglobinopathies Market Share by Application in 2022 & 2028
Figure 26. United States Hemoglobinopathies Market Size by Application (2017-2028) & (US$ Million)
Figure 27. United States Hemoglobinopathies Market Share by Application (2017-2028)
Figure 28. North America Hemoglobinopathies Market Size Growth Rate 2017-2028 (US$ Million)
Figure 29. U.S. Hemoglobinopathies Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 30. Canada Hemoglobinopathies Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 31. Europe Hemoglobinopathies Market Size Growth Rate 2017-2028 (US$ Million)
Figure 32. Germany Hemoglobinopathies Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 33. France Hemoglobinopathies Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 34. U.K. Hemoglobinopathies Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 35. Italy Hemoglobinopathies Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 36. Russia Hemoglobinopathies Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 37. Asia-Pacific Hemoglobinopathies Market Size Growth Rate 2017-2028 (US$ Million)
Figure 38. China Hemoglobinopathies Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 39. Japan Hemoglobinopathies Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 40. South Korea Hemoglobinopathies Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 41. India Hemoglobinopathies Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 42. Australia Hemoglobinopathies Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 43. Taiwan Hemoglobinopathies Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 44. Indonesia Hemoglobinopathies Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 45. Thailand Hemoglobinopathies Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 46. Malaysia Hemoglobinopathies Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 47. Philippines Hemoglobinopathies Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 48. Latin America Hemoglobinopathies Market Size Growth Rate 2017-2028 (US$ Million)
Figure 49. Mexico Hemoglobinopathies Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 50. Brazil Hemoglobinopathies Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 51. Argentina Hemoglobinopathies Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 52. Middle East & Africa Hemoglobinopathies Market Size Growth Rate 2017-2028 (US$ Million)
Figure 53. Turkey Hemoglobinopathies Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 54. Saudi Arabia Hemoglobinopathies Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 55. U.A.E Hemoglobinopathies Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 56. Gamida Cell Revenue Growth Rate in Hemoglobinopathies Business (2017-2022)
Figure 57. Alnylam Pharmaceuticals Revenue Growth Rate in Hemoglobinopathies Business (2017-2022)
Figure 58. Sanofi Revenue Growth Rate in Hemoglobinopathies Business (2017-2022)
Figure 59. Sangamo Therapeutics Inc. Revenue Growth Rate in Hemoglobinopathies Business (2017-2022)
Figure 60. Global Blood Therapeutics Revenue Growth Rate in Hemoglobinopathies Business (2017-2022)
Figure 61. Bluebird Bio Revenue Growth Rate in Hemoglobinopathies Business (2017-2022)
Figure 62. Emmaus Life Sciences Inc. Revenue Growth Rate in Hemoglobinopathies Business (2017-2022)
Figure 63. Prolong Pharmaceuticals Revenue Growth Rate in Hemoglobinopathies Business (2017-2022)
Figure 64. Celgene Corporation Revenue Growth Rate in Hemoglobinopathies Business (2017-2022)
Figure 65. Bottom-up and Top-down Approaches for This Report
Figure 66. Data Triangulation
Figure 67. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
Gamida Cell Alnylam Pharmaceuticals Sanofi Sangamo Therapeutics Inc. Global Blood Therapeutics Bluebird Bio Emmaus Life Sciences Inc. Prolong Pharmaceuticals Celgene Corporation